+34 93 402 04 56 info@proteodesign.es


Our platform has been validated in several collaborations with top tier partners

Partnering with ProteoDesign

Partnering has been at our core since the company’s inception. Our strategy has enabled ProteoDesign to further validate our SEPL platform for the development of next-generation therapeutics in several areas with top tier collaborators from the academy and the industry.

Our aim is to continue pursuing and building such long-term relationships with both academic and industrial partners interested in developing the next-generation of biologics. You can contact Gerard, our Director of Business Development, for such purpose: gerard.caelles@proteodesign.es

Fc-synthetic peptide conjugates

To extend the half-life of synthetic peptide.
Frutos S., Org. Biomol. Chem. 2016.

Undisclosed biotherapeutics

To optimize therapeutic properties.


Single domain antibody conjugates

To deliver cargoes conjugated to sdAb.

Antibody-oligonucleotide conjugates

To boost innate immunity.
Barbuto S., Nat. Chem. Biol. 2013.

Undisclosed biotherapeutics

To enable personalized therapeutics.